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1. Introduction  
Urinary tract infections (UTIs) are a significant source of morbidity and mortality, despite 
the widespread use of antibiotics. Prostatitis is a prevalent and debilitating disease, 
representing the most common urological diagnosis in men under the age of 50 years. 
Despite its prevalence and its drain on health care resources, our understanding of the 
etiology, diagnosis and treatment of prostatitis has not advanced to a widely accepted level.  
Recently, a consensus has been reached on the definition and classification of prostatitis. 
Traditionally, prostatitis has been classified into the four clinical entities: i) Acute bacterial 
prostatitis (ABP), ii) Chronic bacterial prostatitis (CBP) iii) Non or abacterial prostatitis 
(NBP), iv) Prostatodynia. To improve the definition and understanding of prostatitis a new 
classification system has been proposed by the National Institute of Health (NIH). It 
includes: i) ABP, ii) CBP, represents the traditional forms of acute and chronic bacterial 
prostatitis, defined by the presence of both prostatic inflammation and uro-pathogenic 
bacteria in prostatic culture, iii) Chronic pelvic pain syndrome (CPPS) with the 
inflammatory and non-inflammatory type, which is characterized by prostatitis like 
symptoms  in the absence of bacterial localization to the prostate  iv) asymptomatic 
inflammatory prostatitis, which is characterized by pathogenic evidence of prostatic 
inflammation in patients without symptoms (includes patients who have prostatic 
inflammation diagnosed after prostatic biopsy) (Magri et al., 2010).  
Risk factors that allow bacterial colonization and/or infection of the prostate with 
potentially pathogenic bacteria include intraprostatic ductal reflux; phimosis; specific blood 
groups; unprotected anal intercourse; UTI; acute epididymitis; indwelling urethral or 
condom catheters; and transurethral operations (especially in men who have infected urine) 
(Westesson & Shoskes, 2010). 
In a study, nearly 9.7% of male respondents (aged 20 to 74 years) reported pain or discomfort 
in the perineum or with ejaculation or both, plus a total pain score (possible 0 to 21) of 4 or 
greater (Vaidyanathan & Mishra, 2008). This location and level of pain would be sufficient to 
lead most physicians to make a diagnosis of chronic prostatitis (CP). In this age group, 6.6% of 
men reported similar symptoms over the previous week with a pain score of 8 or greater, 
which would place them in the moderate or severe category (Vaidyanathan & Mishra, 2008). 
The modern era of prostatitis management began in the 1960s with Meares and Stamey's 
description of the four-glass lower urinary tract segmented localization study. With this 
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insight, prostatic massage as the mainstay of prostatitis therapy was abandoned, and 
antimicrobial therapy was rationalized for the percentage of patients with bacteria.  
Unfortunately, the vast majority of patients who were diagnosed with a nonbacterial cause 
continued to suffer the indignities of dismal urologic management (Wagenlehner & Naber, 
2009). 
2. Acute bacterial prostatitis (ABP) 
2.1 Etiology & pathogenesis 
ABP is a generalized infection of the prostate gland and is associated with both lower UTI 
and generalized sepsis. The most common cause of bacterial prostatitis is the 
Enterobacteriaceae family of gram-negative bacteria, which originate from the 
gastrointestinal flora. Aerobic gram-negative organisms principally cause ABP. The 
incidence of infection by various species and their antibiotic susceptibilities follow those of 
organisms that regularly infect the urine (Bruyere, 2010).  
E. coli is implicated in 80% of infections. Pseudomonada aeroginosa, Serratia, Klebsiella and 
Proteas species account for 10-15% of the cases and enterococci for 10-15%. Bacteria reside 
deep in the ducts of the prostate gland and tend to form aggregates (also called bio-films); 
this appears to be a protective mechanism that allows bacteria to persist in the prostate 
gland even when the concomitant cystitis is treated with antibiotics (Bruyere, 2010). 
The gram-positive bacteria become pathogenic only under special circumstances. Anaerobes 
infections are usually polymicrobial. Most infections occur in the peripheral zone, where the 
ducts drain horizontally into the urethra, facilitating reflux of urine as well as intraductal 
stasis. Glands of the central zone empty obliquely and completely into the prostatic urethra, 
preventing easy reflux and stagnation. Invasion by rectal bacteria, either directly or via 
lymphogenous spread, has also been suggested to cause prostatitis (Maglakelidze, 2009).  
Investigators have demonstrated that urine and its metabolites (i.e. urate) are present in the 
prostatic secretion of patients with CP. Prostatic inflammation and subsequent symptoms 
may be simply due to a chemically induced inflammation secondary to the noxious 
substances in the urine that have refluxed into the prostatic duct (Bruyere, 2010). 
2.2 Clinical features   
ABP is marked by fever and chills; rectal, low back, and perineal pain; urinary urgency, 
frequency and dysouria. Prostatic swelling may result in acute urinary retention. Malaise, 
arthralgia, and myalgia are also common. Digital rectal examination reveals an exquisitely 
tender, enlarged gland that is irregularly firm and warm. The urine may be cloudy and 
malodorous because of concomitant UTI. Gross hematuria may be observed occasionally. 
Physical examination is an important part of the evaluation of a patient with prostatitis, but 
it is usually not helpful in making a definitive diagnosis or further classifying prostatitis. It 
assists in ruling out other perineal, anal, neurologic, pelvic, or prostate pathologies and is an 
integral part of the lower urinary tract evaluation. 
In ABP, the patient may be systemically toxic: flushed, febrile, tachycardic, tachypnoic, and 
even hypotensive. The patient usually has suprapubic discomfort due to a degree of urinary 
retention. Perineal pain and anal sphincter spasm may complicate the digital rectal 
examination. The prostate itself is usually described as warm, buggy, and exquisitely tender. 
In cases of ABP, prostatic massage is believed to be unnecessary and even harmful (Erlikh et 
al., 2009). 
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2.3 Diagnosis  
ABP is often diagnosed on the basis of symptoms and physical examination. A complete 
blood count typically shows leukocytosis with a shift toward immature forms. Transurethral 
catheterization as well as prostatic massage should be avoided. Acute urinary retention 
requiring bladder drainage should be managed with a suprapubic tube. The voided urine 
usually shows pyuria and microscopic hematuria due to a UTI (Bruyere, 2010). 
2.4 Management  
Empiric treatment should not be delayed, and should be directed primarily against gram-
negative rods and enterococci. Patients will often respond dramatically to agents that would 
otherwise diffuse poorly into prostatic tissue. The choice of antibiotic is ultimately guided 
by in vitro susceptibility tests. The flouroquinolones work very well as initial therapy, as 
does TMP-SMX. The recommended duration of antibiotic treatment is 4-6 weeks in order to 
prevent the development of complications such as prostatic abscess and chronic prostatitis. 
Supportive measures include antipyretics, analgesics, stool softeners, hydration and bed 
rest. Patients with significant co morbidities, sepsis, immunodeficiency and acute urinary 
retention need hospital admission. Any transurethral catheterization or instrumentation is 
contraindicated during the phase of acute infection. Acute urinary retention should be 
managed with suprapubic drainage until the patient is able to void spontaneously (Weidner 
et al., 2008). 
2.5 Complications  
Some patients may progress to chronic bacterial prostatitis, especially if attention is not 
focused on bacterial eradication. Prostatic abscess can develop in the setting of acute 
prostatitis. Immunocompromised patients, diabetics, those with indwelling urethral 
catheters, or those on chronic dialysis are at higher risk for this complication (Weidner et al., 
2008). 
3. Chronic bacterial prostatitis (CBP)  
3.1 Etiology & pathogenesis 
Chronic bacterial prostatitis is associated with recurrent lower UTIs secondary to focal 
uropathogenic bacteria residing in the prostate gland. Gram-negative bacteria and 
enterococci are usually the causative microorganisms in CBP. Mycoplasms, ureoplasms and 
chlamydial species are appreciable pathogens in BCP and most of them are also implicated 
in the chronic pelvic pain syndromes. Intraprostatic reflux, ductal anatomy, secretory 
dysfanction and alkaline prostatic secretions contribute to CBP.  
Reflux of urine and possibly bacteria into the prostatic ducts has been postulated as one of 
the most important etiologic mechanisms involved in the pathogenesis of chronic bacterial 
and nonbacterial prostatic inflammation. Anatomically, the ductal drainage of the 
peripheral zone is more susceptible than other prostatic zones to intraprostatic ductal reflux 
(Wagenlehner et al., 2008). Investigators have measured high levels of urate and creatinine 
in EPS, which they postulated was caused by urine reflux into the prostatic ducts (Touma & 
Nickel, 2010). Furthermore, carbon particles have been found in the EPS macrophages and 
prostatic acini and ductal system after surgery in men with nonbacterial prostatitis. 
Bacterial microcolonies may adhere to ductal and acinar walls and become impervious to 
antibiotics. Prostatic calculi also provide sanctuary for pathogens. A large proportion of men 
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with CBP have multiple prostatic calculi demonstraded on transrectal ultrasound. Prostatic 
calculi can serve as a source for bacterial persistence and recurent UTIs.  
It is believed that the source of the pain is located at the pelvic  area of the sacrum, coccyx, 
ischial tuberosity, pubic rami, and endopelvic fascia (Saini et al., 2008). These areas are 
immediately adjacent to the prostate and bladder and can be recognized by the 
demonstration of a hyperirritable spot (myofascial trigger point) that is painful on 
compression. It is hypothesized that the formation of myofascial trigger points in this area 
may be correlated with mechanical abnormalities in the hip and lower extremities, toilet 
straining, sexual abuse, repetitive trauma, constipation, heavy sports, trauma or unusual 
sexual activity, recurrent infections, and surgery (Sandhu, 2008). 
3.2 Clinical features  
The physical examination of a patient with category II CBP and category III CPPS is usually 
unremarkable. Careful examination and palpation of external genitalia, groin, perineum, 
coccyx, external anal sphincter, and internal pelvic side walls may pinpoint prominent areas 
of pain or discomfort (Magri et al., 2010). The digital rectal examination should be 
performed after the patient has produced pre- prostatic massage urine specimens. The 
prostate may be normal in size and consistency, and it has also been described as enlarged 
and boggy. The degree of elicited pain during prostatic palpation is variable and is 
unhelpful in differentiating a prostatitis syndrome. The prostate should be carefully checked 
for prostatic nodules before a vigorous prostatic massage is performed (Westesson and 
Shoskes, 2010). 
Most patients report dysuria as well as urgency, frequency, and nocturia. Low back and 
perineal pain or discomfort may be present. The natural history is marked by disease 
relapse with occasional acute exacerbations, at which time fever, chills and malaise might 
manifest. Sometimes, the diagnosis is made in an asymptomatic patient in whom bacteriuria 
is found incidentally. There are no characteristic findings on digital rectal examination. The 
prostate frequently feels normal although tenderness, swelling, and firmness may be 
present. Secondary epididymitis is sometimes present. Hematuria, hematospermia and 
urethral discharge are usually rare (Jonsson & Hedelin, 2008). 
3.3 Diagnosis  
The 4-glass test is the standard in prostatitis diagnosis. This technique allows localization of 
bacteria by examining specimens from the urethra, midstream urine, and prostatic se-
cretions. The examiner obtains the first voided 10 mL of urine (urethral specimen), a late 
midstream sample (bladder specimen), a specimen of prostatic secretions following prostatic 
massage, and the first voided 10 mL of urine following the massage. The specimens are 
labeled VB1, VB2, EPS, and VB3, respectively, and they are sent for bacterial identification 
and quantification using standard microbiologic methods. Two or more bacterial 
localization tests may then be required to identify the pathogenic bacteria. If no organisms 
can be cultured, and the prostatic fluid has increased leukocyte count (> 10 per HPF), a 
diagnosis of chronic pelvic pain syndrome (inflammatory type) can be made (Westesson & 
Shoskes, 2010). Despite sterilization in the urine, the pathogen often remains sheltered in the 
prostate because most antibiotics diffuse poorly into prostatic fluid. The prostate-specific 
antigen may be elevated.  
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3.4 Management  
At least 3-4 months of treatment is generally recommended, although some studies have 
reported success with a 4-week course of a fluoroquinolone. Factors that promote antibiotic 
diffusion into the prostate include lipid solubility, weak binding to plasma proteins, and an 
uncharged state. Suppressive antibiotic therapy aimed at eliminating bacterial growth in the 
urine is often instituted. Most antibiotics are concentrated in the urine, allowing for reduced 
dosing while maintaining bactericidal efficacy. The most common daily suppressive 
regimens are nitrofurantoin (100 mg daily), TMP-SMX (200 mg daily), and ciprofloxacin (250 
mg daily). Suppressive therapy can provide relief from symptoms for most men. 
Transurethral prostatectomy (TURP) has been described as an alternative treatment. 
Surgical therapy often provides the only chance at cure in relapsing cases. Studies of 
patients undergoing TURP for chronic bacterial prostatitis followed by 6-8 weeks of 
antibiotic therapy report varying success rates (30%-100%).  
3.5 Complications  
Recurrent UTIs are a major complication of CBP that may even result to infertility. Reports 
of successful treatment of prostatitis leading to improvement in semen parameters and 
pregnancy rates have been made. Although more difficult to quantify, CBP has a negative 
impact on the patient’s quality of life. 
4. Chronic pelvic pain syndrome (CPPS) 
4.1 Etiology & pathogenesis 
CPPS is the most common form of prostatitis and the most poorly understood. CPPS 
categories are divided into inflammatory (category IIIA) and noninflammatory (category 
IIIB) forms, based on the presence of leukocytes in the prostatic fluid. The inflammatory 
type was previously called “nonbacterial prostatitis” (associated with elevated prostatic 
immunoglobulin level); while the non-inflammatory type was called “prostatodynia” (not 
associated with increased immunoglobulins). Several studies have demonstrated chlamydial 
antigens in the prostatic fluid and anti-chlamydial antibodies in the serum of men with 
CPPS. In a study, transperineal prostate biopsy of men with CPPS failed to detect chlamydia 
by either immunofluorescence or culture (Wagenlehner et al., 2008). There seems to be an 
association between backflow of urine into the prostatic ducts and a subsequent chemically 
induced inflammatory prostatitis. Backflow of urine could lead to high concentrations of 
urinary urate and creatinine in the prostate fluid, resulting in a chemical prostatitis. 
Investigators have demonstrated a positive correlation between leukocyte count and urate 
concentration in the prostate fluid (Touma & Nickel, 2010).  
Anatomic or neurophysiologic obstruction resulting in high-pressure dysfunctional flow 
patterns has been implicated in the pathogenesis of prostatitis. Urodynamic studies confirm 
that many patients, particularly those with prostatodynia, have obstructive flow rate 
patterns (e.g. decreased maximal flow rate). During video-urodynamic studies, many 
patients with prostatitis show incomplete funneling of the bladder neck as well as 
vesicourethral dysynergic patterns. Dysynergic voiding may lead to autonomic 
overstimulation of the perineal-pelvic neural system with subsequent development of a 
chronic neuropathic pain state. Alternatively, dysfunctional voiding may result in 
intraprostatic ductal reflux (Hedelin & Fall, 2008). Investigators have found an increased 
maximal urethral closure pressure and a decreased urinary flow rate in patients with CPPS 
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compared with control patients (Strauss & Dimitrakov, 2010). They attributed the high 
maximal urethral closure pressure to increased adrenergic stimulation in the proximal 
urethra and bladder neck and proposed that this might cause intraprostatic reflux of urine. 
Based on these observations they suggested the use of the term "painful male urethral 
syndrome". Furthermore, spasm of the pelvic floor muscles alone or in combination with 
bladder neck dysfunction may contribute to chronic pelvic pain (Strauss & Dimitrakov, 
2010). 
4.2 Clinical features  
Voiding dysfunction consisting of dysuria, slow stream, urgency, and frequency. Sexual 
dysfunction may also be reported. On digital rectal examination the prostate may be tender. 
During palpation patients may have tenderness of the pelvic floor muscles and a tight anal 
sphincter (Dellabella et al., 2009). 
4.3 Diagnosis 
The EPS in patients with inflammatory CPPS shows numerous leukocytes and lipid-laden 
macrophages. A 5-fold increase in leykocytes and an 8-fold increase in lipid-laden 
macrophages may be revealed in such patients in comparison control subjects. Urodynamic 
studies may disclose urethral hypertonia and diminished flow in the absence of striated 
sphincter dyssynergia (Vaidyanathan & Mishra, 2008).   
4.4 Management 
Patients may experience symptomatic improvement with antibiotics. This has prompted the 
recommendation of a trial of antibiotic therapy. If chlamydia is suspected, then tetracycline, 
minocycline, doxycycline or erythromycin should be administered. Antibiotic therapy 
should continue for several weeks. Alpha blockers may improve urination and symptoms. 
By decreasing adrenergic tone in the proximal urethra, alpha blockers alleviate urethral 
hypertonia and may prevent intraprostatic reflux of urine. Intraprostatic ductal reflux of 
urine increases the concentration of metabolites containing purine and pyrimidine bases in 
the prostatic ducts, resulting in inflammation (Sandhu, 2008). 
High concentrations of urate in urine can be reduced with the use of allopurinol, a xanthine 
oxidase inhibitor. This may alleviate chemical irritation in the prostate caused by refluxed 
urine. Studies have demonstrated a significant effect of allopurinol on urate concentration in 
the prostatic fluid resulting in symptoms improvement (Maglakelidze 2009). Pelvic floor 
relaxation techniques, biofeedback, prostate massage, and muscle relaxants may reduce 
pelvic floor spasticity and chronic pelvic pain (Maglakelidze, 2009). Interestingly, a pollen 
extract (Cernilton) was recently assessed in a multicentre, prospective, randomised, double-
blind, placebo-controlled phase 3 study (Wagenlehner, 2009). Participants were randomised 
to receive oral capsules of the pollen extract or placebo for 12 weeks. Compared to placebo, 
the pollen extract significantly improved total symptoms, pain, and QoL in patients with 
inflammatory CP/CPPS without severe side-effects. 
Prostatic inflammation is associated with category III CPPS, while elevated cytokine levels 
are noted in the semen and EPS of patients with inflammatory CPPS. Non-steroidal anti-
inflammatory drugs, steroids, and immunosuppressive medication theoretically may 
improve the symptoms. Surgical therapy with transrurethral microwave thermotherapy or 
neodynium:YAG laser has also been suggested (Hedelin & Fall, 2008). 
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4.5 Complications  
CPPS may have a negative effect in fertility. Lower sperm counts and abnormal 
morphologic and motility parameters have been described in affected patients. These 
parameters may worsen with time. As with chronic bacterial prostatitis, the quality of life is 
adversely affected (Jonsson & Hedelin, 2008). 
5. Epilogue  
ABP can be efficiently treated with antibiotics that will eventually eradicate the bacteria. 
CBP treatment is based on long  term antibiotic regimens. CP/CPPS management needs 
multimodal medication with antibiotics, alpha blockers, anti-inflammatory drugs and 
hormonal agents (Westesson & Shoskes, 2010). 
Chronic nonbacterial prostatitis and prostatodynia (category III CPPS) constitute the vast 
majority of prostatitis cases and are difficult to manage. Performing a lower urinary tract 
evaluation (at least a two-glass premassage and postmassage screen) to rule out uro-
pathogens, microscopy of postprostatic massage urine sediment (to differentiate 
inflammatory from non-inflammatory CPPS), and employment of the newly validated NIH-
CPSI will allow optimal management (Strauss & Dimitrakov, 2010). Available treatments 
include: i) antibiotics that cover potential pathogens (including Chlamydia and Ureaplasma, 
at least in category IIIA); ii) alpha blockers (especially in patients with obstructive voiding 
symptoms); iii) anti-inflammatory agents; iv) muscle relaxants; v) pento-san polysulfate (in 
patients with bladder or interstitial cystitis-like symptoms); and vi) physical therapy (i.e. 
prostate, perineal, or pelvic floor massage, myofascial trigger point release, and 
biofeedback). For refractory symptoms, other treatment modalities include microwave 
hyperthermia or thermotherapy and TURP (Magri et al., 2010). 
Asymptomatic inflammatory prostatitis (category IV) does not require symptomatic 
therapy. However, antibiotic medication may be indicated in patients who are scheduled to 
undergo endoscopic procedures, and in patients with concomitant inflammation and 
infertility (Murphy et al., 2009). 
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